Factors associated with virological failure in people with HIV treated with bictegravir/emtricitabine/tenofovir alafenamide. Impact of pre-existing mutations and risk of resistance emergence. ANRS-CO3-AquiVIH-NA cohort

Le résumé fourni par la source

OBJECTIVES: We investigated, in a real-world setting, virological factors associated with virological failure (VF) after bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) initiation in people with HIV (PWH) with and without pre-existing drug resistance mutation (PRM) and the emergence of new resistance mutations at virological failure. METHODS: Treatment-experienced PWH from ANRS-CO3-AquiVIH-NA cohort starting B/F/TAF between 2018 and 2021 were stratified depending on their baseline viral load (VL): virologically suppressed (VS; VL <50 copies/mL) and virologically unsuppressed (VU; VL >50 copies/mL). PRM were identified using cumulative genotypic resistance tests (GRT) according to the ANRS algorithm. Factors associated with VF were analysed using a Cox proportional hazards model and survival curves. RESULTS: Among the 636 PWH with available GRT results, 82.7% were VS at B/F/TAF initiation. PRMs to at least one component of B/F/TAF were present for 23.1% of participants (20.9% VS and 33.6% VU), with the M184I/V mutation identified in 89.1% of cases (88.2% in VS and 91.9% in VU). Virological success was higher for those with no PRMs (92.8% no PRM vs 86.4% with PRM). VU PWH had a higher risk of VF [HR 9.53 (5.54-16.40)]. Among the 66 PWH with baseline GRT experiencing VF, new resistance mutations were selected for six (two VU and four VS). After VF, B/F/TAF was maintained for 56/66 (84.8%) participants, of whom 40/56 (71.4%) had a VL <50 copies/mL at their last visit. CONCLUSIONS: Virological suppression was maintained in VS PWH regardless PRMs but to a less extent in VU PWH. Emergence of new resistance mutation occurred rarely in the case of VF.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.